Julia Junge and Richard Junge, v. Geron Corp. and John Scarlett, No. C 20-00547 WHA(N.D. Cal.) USDC – Northern District of California Class Period: March 19, 2018 – September 26, 2018 Attorneys: Robert N. KaplanRKaplan@kaplanfox.comJeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.comKathleen HerkenhoffKHerkenhoff@kaplanfox.comJason A. Uris JUris@kaplanfox.comBlair E. ReedBReed@kaplanfox.com Kaplan Fox is the court-appointed lead counsel in this securities class action on behalf of all purchasers of Geron common stock between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”), who were damaged thereby (the “Class”). Kaplan Fox is the court-appointed lead counsel in this securities class action on behalf of all purchasers of Geron common stock between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”), who were damaged thereby (the “Class”). The claims asserted herein are alleged against Geron, and the Company’s President and Chief Executive Officer (“CEO”) John A. Scarlett (“Scarlett”), and arise under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”),15 U.S.C. §§ 78j(b) and 78t(a), and SEC Rule 10b-5, 17 C.F.R. § 240.10b-5, promulgated thereunder. A copy of the Consolidated Amended Complaint can be found here. On April 12, 2021, the Court granted in part and denied in part Defendants’ motion to dismiss. A copy of the Court’s order can be found here. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Charles River Laboratories International, Inc. See the Case Digital Currency Group, Inc. See the Case Spectrum Pharmaceuticals, Inc. See the Case Co-Diagnostics, Inc. See the Case Vale SA See the Case Geron Corporation See the Case Hecla Mining Company See the Case Textron Inc. See the Case Ambac Financial Group Securities Litigation See the Case Citigroup CSO Hedge Fund Class Action See the Case Eletrobras Securities Litigation See the Case Envision Healthcare Class Action See the Case
